MedTrace Logo

Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients

NCT06665880 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2024-10-30

No results posted yet for this study

Summary

In patients with drug-resistant epilepsy (DRE), there may be changes at the genetic, proteomic, and metabolomic levels when comparing epileptic tissues from DRE to normal tissues in traumatic brain injury (TBI). These changes could help in understanding the pathophysiological mechanisms of epilepsy and in identifying new therapeutic targets.

Conditions

  • Drug Resistant Epilepsy
  • Traumatic Brain Injury Without Open Intracranial Wound

Interventions

OTHER

Routine clinical treatment

Routine clinical treatment is based on the latest international guidelines for DRE.

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Guoguang Zhao, MD & PhD · Xuanwu Hospital, Beijing

  • Hongxing Wang, MD & PhD · Xuanwu Hospital, Beijing

  • Yongzhi Shan, MD & PhD · Xuanwu Hospital, Beijing

Eligibility

Min Age
14 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2025-12-15
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06665880 on ClinicalTrials.gov